Warning! GuruFocus detected
6 Severe warning signs
with 9II.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Biovica International AB
ISIN : SE0008613731
Compare
Compare
Traded in other countries / regions
BIOVIC B.Sweden9II.Germany IPO Date
2020-12-16Description
Biovica International AB is a biotech company. The company develops and commercializes blood-based diagnostic tests with biomarkers that improve the monitoring and evaluation of modern cancer treatments. The company promotes healthcare through collaboration with cancer institutes and pharmaceutical companies. DiviTum is manufactured by the company and sold as a kit consisting of a reaction plate with reagents that have been optimized for ELISA applications.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.11 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -9.26 | |||||
| Beneish M-Score | -3.14 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 20.7 | |||||
| 3-Year EBITDA Growth Rate | -20.2 | |||||
| 3-Year EPS without NRI Growth Rate | -15 | |||||
| 3-Year FCF Growth Rate | -15 | |||||
| 3-Year Book Growth Rate | -43.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 40.48 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 157.13 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.67 | |||||
| 9-Day RSI | 31.75 | |||||
| 14-Day RSI | 32.49 | |||||
| 3-1 Month Momentum % | -0.41 | |||||
| 6-1 Month Momentum % | -26.53 | |||||
| 12-1 Month Momentum % | -23.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.73 | |||||
| Quick Ratio | 2.64 | |||||
| Cash Ratio | 2.39 | |||||
| Days Inventory | 585.9 | |||||
| Days Sales Outstanding | 61.85 | |||||
| Days Payable | 978.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -43.3 | |||||
| Shareholder Yield % | -34.12 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 84.03 | |||||
| Operating Margin % | -1316.57 | |||||
| Net Margin % | -1299.63 | |||||
| FCF Margin % | -1130.01 | |||||
| ROE % | -112.38 | |||||
| ROA % | -88.81 | |||||
| ROIC % | -187.94 | |||||
| 3-Year ROIIC % | -555.93 | |||||
| ROC (Joel Greenblatt) % | -1442.99 | |||||
| ROCE % | -106.79 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 10.85 | |||||
| PB Ratio | 1.51 | |||||
| Price-to-Tangible-Book | 2.66 | |||||
| EV-to-EBIT | -0.56 | |||||
| EV-to-Forward-EBIT | -1.02 | |||||
| EV-to-EBITDA | -0.62 | |||||
| EV-to-Forward-EBITDA | -1.02 | |||||
| EV-to-Revenue | 7.35 | |||||
| EV-to-Forward-Revenue | 2.08 | |||||
| EV-to-FCF | -0.65 | |||||
| Price-to-GF-Value | 0.19 | |||||
| Price-to-Net-Current-Asset-Value | 3.57 | |||||
| Price-to-Net-Cash | 4.54 | |||||
| Earnings Yield (Greenblatt) % | -178.57 | |||||
| FCF Yield % | -95.08 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biovica International AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.713 | ||
| EPS (TTM) (€) | -0.104 | ||
| Beta | 1.55 | ||
| 3-Year Sharpe Ratio | -0.78 | ||
| 3-Year Sortino Ratio | -0.91 | ||
| Volatility % | 80.11 | ||
| 14-Day RSI | 32.49 | ||
| 14-Day ATR (€) | 0.007761 | ||
| 20-Day SMA (€) | 0.10997 | ||
| 12-1 Month Momentum % | -23.46 | ||
| 52-Week Range (€) | 0.067 - 0.24 | ||
| Shares Outstanding (Mil) | 97.79 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biovica International AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biovica International AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Biovica International AB Frequently Asked Questions
What is Biovica International AB(STU:9II)'s stock price today?
The current price of STU:9II is €0.08. The 52 week high of STU:9II is €0.24 and 52 week low is €0.07.
When is next earnings date of Biovica International AB(STU:9II)?
The next earnings date of Biovica International AB(STU:9II) is 2025-06-18.
Does Biovica International AB(STU:9II) pay dividends? If so, how much?
Biovica International AB(STU:9II) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers